Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: A clinicopathological study using fluorescence in situ hybridization

Neuropathology

Volumn 27, Issue 1, 2007, Pages 10-20

  Jeon, Yoon Kyung ^a   Park, Kyeongmee ^a   Park, Chul Ki ^b   Paek, Sun Ha ^b   Jung, Hee Won ^b   Park, Sung Hye ^a  

^a Seoul National University   (South Korea)

^b Inje University   (South Korea)

Author keywords

19q; 1p; Oligodendroglioma; p16; p53; TP53 mutation

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, P16; GENES, P53; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846464196     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00735.x     Document Type: Article

References (28)

1. Reifenberger G, Kros JM, Burger P, Louis DN, Collins VP. Oligodendroglioma. In: Kleihues P, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 2000; 56-67.
2. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479.
3. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 2001; 4 (Suppl 13): 13-18.
4. Bigner SH, Matthews MR, Rasheed BKA et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999; 155: 375-386.
5. Smith JS, Alderete B, Minn Y et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999; 18: 4144-4152.
6. van den Bent MJ, Looijenga LH, Langenberg K et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97: 1276-1284.
7. Smith JS, Perry A, Borell TJ et al. Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-645.
8. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-845.
9. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neurooncology. J Neuropathol Exp Neurol 2003; 62: 111-126.
10. Burger PC, Minn Y, Smith JS et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001; 14: 842-853.
11. Megyesi JF, Kachur E, Lee DH et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10: 4303-4306.
12. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. TP53 mutations in nonastrocytic human brain tumors. Cancer Res 1991; 51: 6202-6205.
13. Hagel C, Lacking G, Laas R et al. Demonstration of p53 protein and TP53 gene mutation in oligodendrogliomas. Eur J Cancer 1996; 32A: 2242-2248.
14. Ueki K, Nishikawa R, Nakazato Y et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.
15. Kros JM, Godschalk JJCJ, Krishnadath KK, van Eden CG. Expression of p53 in oligodendrogliomas. J Pathol 1993; 171: 285-290.
16. Bortolotto S, Chiadò-Piat L, Cavalla P et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000; 88: 554-557.
17. Miettinen H, Kononen J, Sallinen P et al. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999; 41: 205-211.
18. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-1393.
19. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 350-364.
20. Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-3138.
21. Sasaki H, Zlatescu MC, Betensky RA et al. Histopathological- molecular genetic correlation in referral pathologist-diagnosed low-grade 'oligodendroglioma'. J Neuropathol Exp Neurol 2002; 61: 58-63.
22. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190.
23. Bello MJ, Leone PE, Vaquero J et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995; 64: 207-210.
24. Sasatomi E, Johnson LR, Aldeeb DN et al. Genetic profile of cumulative mutational damage associated with early pulmonary adenocarcinoma: bronchioloalveolar carcinoma vs. stage I invasive adenocarcinoma. Am J Surg Pathol 2004; 28: 1280-1288.
25. Walker C, du Plessis DG, Joyce KA et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histologic heterogeneity. Clin Cancer Res 2003; 9: 4841-4851.
26. Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 1998; 58: 4694-4670.
27. Miettinen HE, Pauni N, Rantala I et al. Cell cycle regulators (p21, 53, pRB) in oligodendrocytic tumor: a study by novel tumor microarray technique. J Neurooncol 2001; 55: 29-37.
28. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 2002; 58: 237-253.